Neuroone Medical Technologies (NMTC) EBIT (2010 - 2026)

Neuroone Medical Technologies' EBIT history runs 17 years deep, the most recent figure standing at -$2.4 million for Q1 2026.

• Quarterly EBIT rose 10.55% year-over-year to -$2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.4 million (down 11.9% YoY) and the FY2025 annual result came in at -$4.2 million, up 64.45% from the prior year.
• EBIT was -$2.4 million for Q1 2026 at Neuroone Medical Technologies, down from -$1.7 million in the prior quarter.
• Across five years, EBIT topped out at $1.7 million in Q4 2024 and bottomed at -$3.5 million in Q2 2023.
• A 5-year average of -$2.3 million and a median of -$2.8 million in 2022 frame the typical range for EBIT.
• Annual changes were most pronounced in 2024 — EBIT soared 150.47% — and 2025, when it tumbled 199.77%.
• Neuroone Medical Technologies' EBIT stood at -$1.8 million in 2022, then tumbled by 90.01% to -$3.4 million in 2023, then surged by 150.47% to $1.7 million in 2024, then plunged by 199.77% to -$1.7 million in 2025, then tumbled by 40.41% to -$2.4 million in 2026.
• Business Quant data shows NMTC's EBIT at -$2.4 million in Q1 2026, -$1.7 million in Q4 2025, and -$1.4 million in Q3 2025.